NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line Treatment

NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line Treatment

HMP CME

1 year
370 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-02 This on-demand webcast examines the efficacy and safety, indications, and cost utility of available EGFR tyrosine kinase inhibitors (TKIs) and monoclonal antibodies into optimal first-line selection and NSCLC pathway placement strategies. © 2018 NACCME, an HMP Company
Up Next Autoplay